Having trouble accessing articles? Reset your cache.

Combo Bio-engineered Sirolimus Eluting Stent: Completed Phase II enrollment

OrbusNeich completed enrollment of 183 patients in the open-label, international Phase II REMEDEE

Read the full 134 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE